Document is current
Any future updates will be listed below
-
Authors
Baldini, Chiara https://orcid.org/0000-0002-4454-1824
Fulvio, Giovanni https://orcid.org/0000-0003-0130-4412
La Rocca, Gaetano https://orcid.org/0000-0002-1808-7090
Ferro, Francesco
- License Information
-
More Information
Article History
Accepted: 4 June 2024
First Online: 9 July 2024
Competing interests
: C.B. and F.F. have participated in randomized clinical trials of deucravacitinib (for BMS), belimumab plus rituximab (for GSK), anti-CD40L therapy (for Horizon Therapeutics), anti-CD40 therapy (for Novartis) and anti-CD20 therapy (for Novartis). G.F. and G.L.R. have participated in randomized clinical trials of deucravacitinib (for BMS), anti-CD40L therapy (for Horizon Therapeutics), anti-CD40 therapy (for Novartis) and anti-CD20 therapy (for Novartis). C.B. has served as adviser or consultant for Aurina, GSK, Horizon Therapeutics/AMGEN, Johnson and Johnson and Sanofi.
